FDA Approves IMFINZI Combination With BCG For Non-muscle-invasive Bladder Cancer In Adults

AstraZeneca’s IMFINZI (durvalumab), combined with BCG induction and maintenance therapy, has been approved by the US FDA for adult patients, marking a meaningful regulatory win for the company. The approval supports expansion of IMFINZI’s label in oncology and could incrementally strengthen revenue prospects, though the article does not provide trial data, pricing, or market-share estimates.

Analysis

AstraZeneca’s IMFINZI (durvalumab), combined with BCG induction and maintenance therapy, has been approved by the US FDA for adult patients, marking a meaningful regulatory win for the company. The approval supports expansion of IMFINZI’s label in oncology and could incrementally strengthen revenue prospects, though the article does not provide trial data, pricing, or market-share estimates.